IL17A and colorectal carcinoma: Mechanistic studies revealed that IL-17A upregulated PD-L1 expression via the IL-17A/P65/NRF1/miR-15b-5p axis at the post-transcriptional level in CRC cells, thereby suppressing the efficacy of immunotherapy.